Global Slide Stainers Market (2022 to 2027) - Increasing Number of Clinical Trials Pertaining to Cancer Drugs Presents Opportunities - ResearchAndMarkets.com

The "Global Slide Stainers Market by Product (Reagent (Stains, Probes, ABS), Equipment (Automated, Manual)), Technology (H&E, IHC, ISH, Cytology), Application (Disease Diagnosis (Cancer) Research), End-user (Hospitals, Diagnostic Labs), and Region - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The global slide stainers market is valued at USD 4.3 billion in 2022 and is projected to reach USD 5.9 billion in 2027 at a CAGR of 6.8% from 2022 to 2027.

The reagents & kits segment accounted for the largest share of the slide stainer market in 2021

The slide stainer market by product is further segmented into the slide stainer market is segmented into reagents & kits, equipment, and consumables & accessories. The reagents & kits dominated the slide stainer products with the high usage of the reagent & kits in the diagnosis and research of various diseases such as cancer, infections and other chronic conditions. The lung pathology-related diagnosis and research-related studies have increased the volume of slide staining.

The hematoxyline & eosin segment accounted for the largest share of the slide stainer market in 2021

The slide stainer market by technology is further segmented into the slide stainer market is segmented into hematoxylin & eosin, immunohistochemistry, in situ hybridization, cytology, microbiology, hematology, and special staining. The hematoxylin & eosin dominated the slide stainer products. Hematoxylin & eosin is the most used slide staining technique used for the diagnosis and research of cancer, infectious, and other chronic diseases.

The disease diagnosis application segment is estimated to grow at a rapid rate during the forecast period

Based on application, the slide stainer market is segmented into disease diagnosis and medical research. In 2021, the disease diagnosis application accounted for the largest share of the slide stainer market and is projected to grow at the highest CAGR. The increasing cases of cancer, such as breast cancer, gastric cancer, lymphoma, etc., and infections. The prevalence of cancer and various infections is rising, which has boosted the growth rate of the application segment.

Hospitals & diagnostics centers segment accounted for the largest share of end-users of the slide stainer market in 2021

The end-user segment of the slide stainer market is further segmented into hospitals and diagnostics centers, academic and research institutes, pharmaceutical and biotechnology companies, and other end-users. The dominant share was accounted for by the hospitals and diagnostics centers segment in 2021, which was driven by the high volume of cancer slide staining due to the cancer biopsies, diagnosis and research. Also, the high burden of infections such as COVID-19 and their diagnosis have promoted the segment of the slide stainer end-users.

Asia-Pacific is the fastest-growing regional market for slide stainer

In 2021, the slide stainer market was further divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America region ruled the market in 2021, followed by Europe. Although, the Asia-Pacific region is expected to grow with the fastest growth rate during the forecast period of 2022 to 2027, with the improving healthcare infrastructure, medical investments, vast patient base of geriatric patients and increasing cases of cancer, infections and other chronic complications.

Market Dynamics

Drivers

• Rising Prevalence of Cancer
• Recommendations for Cancer Screening
• Increasing Healthcare Expenditure
• Rising Geriatric Population and Subsequent Growth in Chronic and Infectious Disease Prevalence
• Growing Number of Private Diagnostic Centers Globally
• Increasing Automation in Laboratories
• Increasing Use of AI in Histopathology

Restraints

• High Equipment Cost

Opportunities

• High-Growth Opportunities in Emerging Markets
• Increasing Number of Clinical Trials Pertaining to Cancer Drugs

Challenges

• Dearth of Knowledgeable and Skilled Technicians
• Product Recalls
• Availability of Refurbished Equipment

Companies Mentioned

• Abcam PLC
• Agilent Technologies, Inc.
• Amos Scientific Pty. Ltd.
• Becton, Dickinson and Company
• Bio SB, Inc.
• Biocare Medical, LLC
• BioGenex
• Cell Signaling Technology, Inc.
• CellPath Ltd.
• Dakewe Biotechnology Co. Ltd.
• Danaher
• Diagnostic BioSystems, Inc.
• Diapath S.p.A.
• ELITechGroup
• F. Hoffmann-La Roche Ltd.
• General Data Company, Inc.
• Hardy Diagnostics
• Histo-Line Laboratories
• MEDITE Medical GmbH
• Merck KGaA
• PHC Holdings Corporation
• Rockland Immunochemicals, Inc.
• Sakura Finetek Japan Co. Ltd.
• Siemens Healthineers AG
• SLEE Medical GmbH
• Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/k4f2xt

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005859/en/